Navigation Links
Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
Date:4/15/2011

ction of the BLA by the end of this year, which will complete the application. If approved, metreleptin would be the first therapy indicated specifically for the treatment of diabetes and high triglycerides in patients with lipodystrophy, and the first approved therapeutic use of metreleptin.

About Amylin Pharmaceuticals, Inc.

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.

This press release contains forward-looking statements about Amylin which involve risks and uncertainties.  The actual results for Amylin could differ materially from those discussed due to a number of risks and uncertainties, including that the CMC section of the metreleptin BLA mentioned in this press release may not be submitted in a timely fashion, the estimate of the number of lipodystrophy patients mentioned in this press release may not be accurate, clinical trials or studies may not start when planned, confirm previous results, be predictive of real world use or achieve intended clinical endpoints; preclinical studies may not be predictive; our product candidates, including the product candidate mentioned in this press release, may not receive regulatory approval; and inherent scientific, regulatory and other risks in the drug development and commercialization process. These and additional risks and uncertainties are described more fully in Amyli
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 2013  AbbVie (NYSE: ABBV ) ... clinical study called SONAR (Study Of Diabetic Nephropathy ... investigational compound atrasentan - when added to standard of ... with stage 2 to 4 chronic kidney disease ... large, multinational, double-blind, placebo-controlled clinical study that is ...
(Date:5/19/2013)... ORLANDO, Fla. , May 19, 2013 /PRNewswire/ ... power and low temperature radiofrequency (RF) energy is ... and eliminates or reduces the need for medication ... long-term assessment presented today at the Digestive Disease ... Orlando, Florida . ...
(Date:5/17/2013)... SHANGHAI , May 17, 2013 Medical ... drug nor a biological product. In light of their ... trail evaluations are much more complicated than drug trails ... only evaluates MD safety instead of evaluating both safety ... the US FDA (which is the same as the ...
Breaking Medicine Technology:AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 2Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 3Statistical Challenges in Medical Device Trail Evaluation 2
... Inc., a market leader in PyroCarbon orthopedic implants, announces ... than 40,000 PyroCarbon extremity joint replacements worldwide. ... of Ascension Orthopedics, pioneered efforts using PyroCarbon in the ... His collaborative efforts with the Mayo Clinic lead to ...
... Reportlinker.com announces that a new market research report ... Probiotics and Prebiotics in Clinical Nutrition ... Overall sales of clinical nutrition products are ... EU as well as rising incidence of illnesses and ...
Cached Medicine Technology:Ascension Orthopedics Reaches Milestone With Distribution of 40,000 PyroCarbon Implants 2Reportlinker Adds Probiotics and Prebiotics in Clinical Nutrition 2Reportlinker Adds Probiotics and Prebiotics in Clinical Nutrition 3Reportlinker Adds Probiotics and Prebiotics in Clinical Nutrition 4
(Date:5/20/2013)... , , MONDAY, May 20 (HealthDay News) -- The older ... the late 1990s is more effective than the current ... Teenagers who received four shots with the older vaccine ... years old were significantly less likely to become infected ... compared to children who received all of their immunizations ...
(Date:5/20/2013)... ARBOR, Mich. As high schoolers prepare for final ... "study drug" -- a prescription stimulant or amphetamine -- ... of Michigan poll shows only one in 100 parents ... has used a study drug., Study drugs refer to ... deficit hyperactivity disorder (ADHD); commonly prescribed medicines in this ...
(Date:5/20/2013)... May 20, 2013 Medicare Part D ... satisfied, citing lower costs, convenient access to pharmacies and ... Research Associates released today by the Pharmaceutical Care Management ... (9.5 million) are currently enrolled in plans with preferred ... and overall value of plans with preferred pharmacy networks,” ...
(Date:5/20/2013)... It’s May which means it’s Bike Month! If you ... those dusty bikes and helmets. , Windsong Production's and BLARE ... the office with Windsong Productions challenging BLARE ... miles for the 4th Annual Million Mile Challenge. They may ... *insert battle prep montage* , This is all part of ...
(Date:5/20/2013)... 20, 2013 6Webs.com is the leading ... reviews . 6Webs.com recently completed their assessments of the ... are completed annually and the top home security system ... their monitoring technology, equipment and warranties to mention a ... the 6Webs.com team completed the home security reviews, numerous ...
Breaking Medicine News(10 mins):Health News:Study: Older Whooping Cough Vaccine More Effective 2Health News:Study: Older Whooping Cough Vaccine More Effective 3Health News:1 in 10 teens using 'study drugs,' but parents aren't paying attention 2Health News:Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices 2Health News:Best Home Alarm System Companies in 2013 Published by Leading Security Reviews Site - 6Webs.com 2
... oral drug bosentan (Tracleer) has led to significant improvements ... PAH) // . ,PAH is usually linked with ... cause the overproduction of endothelin, which increases the chance ... obstruction leads to PAH, a condition that in most ...
... shows a diet rich in omega-3 and omega-6 fatty acids may ... Researchers say they studied mice to determine the effects of a ... animals were divided into four groups. The first received a diet ... a diet rich in omega-6 fatty acids along with the drug ...
... to latest research patients who were treated for depression ... vitamin B12 in their blood.// An increasing amount of ... and depression, but the specifics have not been understood. ... of vitamin B12 and the treatment of depression. ...
... researchers find people who get only four hours a night have ... to weight gain. ,An investigation was conducted among 12 ... the study started, after they had slept about four hours a ... hours a night for two nights. Levels of leptin, which sends ...
... the market are losing their effectiveness, since most of ... that the ocean is a new place to look ... microorganisms fill every milliliter of seawater. Each one could ... deadliest diseases. Many marine organisms are already in development ...
... a month’s time from now five-year-old Hussain Abbas and Mohamed ... as normal children.// Part of a contingent of 20 Iraqi ... complicated cardiac problems by the Much Acclaimed heart surgeon Dr ... assessment this evening by a paediatric cardiac physician and are ...
Cached Medicine News:
...
Malis Curette, bayonet, titanium handle, stainless steel shaft, working distance 102 mm, length 203 mm....
Sundt Slim-Line Temporary Vessel Clips used for temporary vascular occlusion during intracranial surgical procedures. Non-magnetic, MP35N, MRI compatible, gold color. Bayonet....
Malis Needle Holders, bayonet, titanium. Working distance 2 1/2" (63 mm). Straight tip with width 0.6 mm....
Medicine Products: